Background
==========

Hepatocellular carcinoma (HCC) is one of the most common tumors in China, and frequently occurs in patients with chronic hepatitis B virus (HBV) infection. Although liver resection and other therapies may improve survival, HCC is rarely cured and with high risk of recurrence and metastasis. Here we present a practical adoptive immunotherapy named \"Smart T\" to prepare multiple tumor antigens activated T lymphocytes *ex vivo*, with a promising outcome in a preliminary clinical applications with HCC patients.

Methods
=======

Auotologous T cells from HCC patients were stimulated with mature DCs pulsed with multiple synthetic HCC-antigen peptides pool. The resulting T cells were infused into patients every 2-3 months with 5-10x10^7^cells/kg body weight for multiple cycles.

Results
=======

The resulting cells are mainly polyfunctional T cells (95% ± 1%) co-expressing INF-γ, TNFα and Granzyme B. The activated T cells generated from HLA-A2^+^patient exhibited greater cytotoxic activity to the HLA-A2^+^HCC cells than to the HLA-A2^-^HCC cells. Up to date, 138 HCC patients have received \"Smart T\" treatments. No toxicity was observed. After 3 cycles of \"Smart T\" treatments, we have detected a significant increase of CD8^+^CD107a^+^T cells (p = 0.0082), effector T cells (p = 0.0013) and central memory T cells (p = 0.0038) in the patients\' PBMCs as well as a significant decrease of regulatory T cells (p = 0.0015). Specific proliferation and IFN-γ production of T cells stimulated by HCC- antigens pool was also detected in the HCC patients\' PBMCs as compared to irrelevant antigen stimulation (Figure [1](#F1){ref-type="fig"}). Moreover, the IFN-γ ELISPOT assay (Figure [2](#F2){ref-type="fig"}) demonstrated specific responses in patients against each kind of peptides, most of them responded to carcinoembryonic antigen (CEA), survivin, vascular endothelial growth factor receptor (VEGFR), alpha fetoprotein (AFP), glypican-3 (GPC3), HBV core antigen and HBV DNA polymerase. A retrospectively clinical analysis revealed that after multiple \"Smart T\" treatments, the recurrence and metastasis incidence in one year was low to 10% in the patients with B stage of HCC (n = 10), compared to B stage HCC patients without \"Smart T\" treatment (n = 14, recurrence and metastasis incidence: 71%, *p*= 0.005, analyzed by Fisher\'s exact 2-sided test).
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Conclusion
==========

Our study, for the first time, demonstrates tumor antigens specific T cell responses can be robustly raised in HCC patients after Smart T treatment, and provides a safe treatment which may improve the immunologic function and clinical outcome of the HCC patients.

Consent
=======

Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
